Safety and tolerability of fexofenadine for the treatment of allergic rhinitis in children 2 to 5 years old

Annals of Allergy, Asthma and Immunology

Volumn 99, Issue 4, 2007, Pages 358-363

  Milgrom, Henry ^a   Kittner, Barbara ^b   Lanier, Robert ^c   Hampel, Frank C ^d  

^a NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

^b SANOFI   (France)

^c North Texas Institute for Clinical Trials   (United States)

^d Central Texas Health Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FEXOFENADINE; PLACEBO;

ACCIDENTAL INJURY; ALLERGIC RHINITIS; ARTICLE; ASTHMA; BLOOD CHEMISTRY; BREATHING RATE; CLINICAL ASSESSMENT; CLINICAL EXAMINATION; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG CAPSULE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCARDIOGRAPHY; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART RATE; HEMATOLOGICAL PARAMETERS; HUMAN; INFECTION; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MOUTH TEMPERATURE; MULTICENTER STUDY; NEUROLOGIC DISEASE; OTALGIA; OTITIS MEDIA; PHARYNGITIS; PHYSICAL EXAMINATION; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINITIS; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; VITAL SIGN;

EID: 35349028244     PISSN: 10811206     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1081-1206(10)60553-4     Document Type: Article

References (24)

1. US Department of Health and Human Services, Agency for Healthcare Research and Quality. Management of allergic and nonallergic rhinitis: summary, evidence report/technology assessment: number 54. Available at: http://www.ahrq.gov/clinic/epcsums/rhinsum.htm. Accessed April 20, 2007.
2. Milgrom H, Leung D. Allergic rhinitis. In: Behrman R, Kliegman R, Jenson H, eds. Nelson Textbook of Pediatrics. Philadelphia, PA: WB Saunders; 2003:759-760.
3. Rimpela A, Savonius B, Rimpela M, Haahtela T. Asthma and allergic rhinitis among Finnish adolescents in 1977-1991. Scand J Soc Med. 1995;23:60-65.
4. Esamai F, Ayaya S, Nyandiko W. Prevalence of asthma, allergic rhinitis and dermatitis in primary school children in Uasin Gishu district, Kenya. East Afr Med J. 2002;79:514-518.
5. Maziak W, Behrens T, Brasky T, et al. Are asthma and allergies in children and adolescents increasing? results from ISAAC phase I and phase III surveys in Munster, Germany. Allergy. 2003;58:572-579.
6. Settipane RA. Complications of allergic rhinitis. Allergy Asthma Proc. 1999;20:209-213.
7. Lack G. Pediatric allergic rhinitis and comorbid disorders. J Allergy Clin Immunol. 2001;108(suppl 1):S9-S15.
8. Spector S. Overview of comorbid associations of allergic rhinitis. J Allergy Clin Immunol. 1997;99:S773-S780.
9. Togias A. Rhinitis and asthma: evidence for respiratory system integration. J Allergy Clin Immunol. 2003;111:1171-1184.
10. Meltzer EO. Quality of life in adults and children with allergic rhinitis. J Allergy Clin Immunol. 2001;108(1 suppl):S45-S53.
11. Vuurman E, van Veggel L, Uiterwijk M, Leutner D, O'Hanlon J. Seasonal allergic rhinitis and antihistamine effects on children's learning. Ann Allergy. 1993;71:121-126.
12. Juniper E, Guyatt G, Dolovich J. Assessment of quality of life in adolescents with allergic rhinoconjunctivitis: development and testing of a questionnaire for clinical trials. J Allergy Clin Immunol. 1994;93:413-423.
13. Meltzer E, Casale T, Nathan R, Thompson A. Once-daily fexofenadine HCl improves quality of life and reduces work and activity impairment in patients with seasonal allergic rhinitis. Ann Allergy Asthma Immunol. 1999;83:311-317.
14. van Cauwenberge P. Advances in allergy management. Allergy. 2002;57(suppl 75):29-36.
15. Okubo K, Gotoh M, Shimada K, Ritsu M, Okuda M, Crawford B. Fexofenadine improves the quality of life and work productivity in Japanese patients with seasonal allergic rhinitis during the peak cedar pollinosis season. Int Arch Allergy Immunol. 2005;136:148-154.
16. Casale TB, Blaiss MS, Gelfand E, et al. First do no harm: managing antihistamine impairment in patients with allergic rhinitis. J Allergy Clin Immunol. 2003;111:S835-S842.
17. 1-antihistamine for the 21st century. Clin Exp All Rev. 2002;2:1-8.
18. Howarth P, Stern M, Roi L, Reynolds R, Bousquet J-P. Double-blind, placebo-controlled study comparing the efficacy and safety of fexofenadine hydrochloride (120 mg and 180 mg once-daily) and cetirizine in seasonal allergic rhinitis. J Allergy Clin Immunol. 1999;104:927-933.
19. Casale TB, Andrade C, Qu R. Safety and efficacy of once-daily fexofenadine HCl in the treatment of autumn seasonal allergic rhinitis. Allergy Asthma Proc. 1999;20:193-198.
20. Graft DF, Bernstein DI, Goldsobel A, Meltzer EO, Portnoy J, Long J. Safety of fexofenadine in children treated for seasonal allergic rhinitis. Ann Allergy Asthma Immunol. 2001;87:22-26.
21. Wahn U, Meltzer EO, Finn AF Jr, et al. Fexofenadine is efficacious and safe in children (aged 6-11 years) with seasonal allergic rhinitis. J Allergy Clin Immunol. 2003;111:763-769.
22. Meltzer EO, Scheinmann P, Rosado Pinto JE, et al. Safety and efficacy of oral fexofenadine in children with seasonal allergic rhinitis: a pooled analysis of three studies. Pediatr Allergy Immunol. 2004;15:253-260.
23. Krishna R, Krishnaswami S, Kittner B, Sankoh A, Jensen B. The utility of mixed-effects covariate analysis in rapid selection of doses in pediatric subjects: a case study with fexofenadine hydrochloride. Biopharm Drug Dispos. 2004;25:373-387.
24. Schoenwetter WF, Dupclay L Jr, Appajosyula S, Botteman M, Pashos C. Economic impact and quality-of-life burden of allergic rhinitis. Curr Med Res Opin. 2004;20:305-317.